CCM
PBYI icon

Coldstream Capital Management’s Puma Biotechnology PBYI Stock Holding History

Coldstream Capital Management’s Portfolio PBYI Stock Details PBYI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-304
Closed -$900 – 2681
2025
Q1 		$900 Buy
+304
New +$952 ﹤0.01% 3210

Other funds holding PBYI

ACA
Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
KCM
Kennedy Capital Management St Louis, Missouri $5.65B AUM 61.31% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Connor, Clark & Lunn Investment Management (CC&L)
Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $52.8B AUM 58.98% 1-Year Est. Return

Coldstream Capital Management's PBYI Position: Q2 2025 in Review

Coldstream Capital Management sold out of Puma Biotechnology (PBYI) in Q2 2025, closing a stake of 304 shares — an estimated $900 sold.

Coldstream Capital Management first reported a position in PBYI in Q1 2025 and held it in 1 quarter. The position peaked at $900 in Q1 2025. 121 funds tracked by Wall St. Rank hold PBYI as of Q2 2025.

  • Coldstream Capital Management reported no remaining Puma Biotechnology position as of Q2 2025 after selling out during the quarter.
  • Coldstream Capital Management sold 304 Puma Biotechnology shares in Q2 2025, an estimated $900.
  • Coldstream Capital Management first reported a position in Puma Biotechnology in Q1 2025 and held it in 1 quarter.
  • Coldstream Capital Management's Puma Biotechnology position peaked at $900 in Q1 2025.
  • 121 funds tracked by Wall St. Rank held Puma Biotechnology as of Q2 2025.

Based on Coldstream Capital Management's 13F filing for Q2 2025, filed 12 Aug 2025.